Panagora Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Panagora Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-206	Closed	–	–	2834
2019 Q2	$0	Sell	206 -38,088	-99%	-$35.2K	﹤0.01%	2767
2019 Q1	$37K	Buy	+38,294	New	+$40.3K	﹤0.01%	2119
2018 Q1	–	Sell	-4,507	Closed	-$12K	–	2479
2017 Q4	$12K	Buy	+4,507	New	+$13.2K	﹤0.01%	2218
2017 Q2	–	Sell	-12,721	Closed	-$53K	–	2758
2017 Q1	$53K	Sell	12,721 -2	-0%	-$9	﹤0.01%	2008
2016 Q4	$51K	Hold	12,723	–	–	﹤0.01%	2098
2016 Q3	$48K	Buy	12,723 +8,196	+181%	+$29.8K	﹤0.01%	2119
2016 Q2	$15K	Hold	4,527	–	–	﹤0.01%	2203
2016 Q1	$24K	Hold	4,527	–	–	﹤0.01%	2120
2015 Q4	$56K	Sell	4,527 -5,056	-53%	-$67.5K	﹤0.01%	1953
2015 Q3	$139K	Buy	+9,583	New	+$166K	﹤0.01%	1717
2014 Q3	–	Sell	-25,976	Closed	-$730K	–	2467
2014 Q2	$730K	Buy	+25,976	New	+$781K	﹤0.01%	1242

Other funds holding CTIC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Panagora Asset Management's CTIC Position: Q3 2019 in Review

Panagora Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2019, closing a stake of 206 shares.

Panagora Asset Management first reported a position in CTIC in Q2 2014 and held it in 11 quarters. The position peaked at $730K in Q2 2014. 43 funds tracked by Wall St. Rank hold CTIC as of Q3 2019.

Panagora Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2019 after selling out during the quarter.
Panagora Asset Management sold 206 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2019.
Panagora Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2014 and held it in 11 quarters.
Panagora Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $730K in Q2 2014.
43 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.